Exchange Traded Concepts’s Vanda Pharmaceuticals VNDA Stock Holding History

Exchange Traded Concepts’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-235,356	Closed	-$993K	–	1441
2023 Q4	$993K	Buy	235,356 +1,894	+0.8%	+$7.64K	0.03%	403
2023 Q3	$1.01M	Buy	+233,462	New	+$1.3M	0.03%	385
2023 Q1	–	Sell	-55,749	Closed	-$412K	–	1292
2022 Q4	$412K	Buy	+55,749	New	+$543K	0.01%	563
2022 Q3	–	Sell	-44,657	Closed	-$487K	–	1328
2022 Q2	$487K	Buy	44,657 +407	+0.9%	+$4.22K	0.01%	522
2022 Q1	$500K	Buy	+44,250	New	+$582K	0.01%	664
2021 Q3	–	Sell	-35,187	Closed	-$757K	–	1243
2021 Q2	$757K	Buy	35,187 +3,003	+9%	+$53.7K	0.02%	383
2021 Q1	$483K	Sell	32,184 -24,812	-44%	-$402K	0.02%	537
2020 Q4	$749K	Buy	56,996 +5,544	+11%	+$66.7K	0.03%	267
2020 Q3	$497K	Buy	51,452 +35,268	+218%	+$377K	0.03%	302
2020 Q2	$185K	Buy	+16,184	New	+$183K	0.03%	483

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Exchange Traded Concepts's VNDA Position: Q1 2024 in Review

Exchange Traded Concepts sold out of Vanda Pharmaceuticals (VNDA) in Q1 2024, closing a stake of 235,356 shares — an estimated $993K sold.

Exchange Traded Concepts first reported a position in VNDA in Q2 2020 and held it in 10 quarters. The position peaked at $1.01M in Q3 2023. 144 funds tracked by Wall St. Rank hold VNDA as of Q1 2024.

Exchange Traded Concepts reported no remaining Vanda Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Exchange Traded Concepts sold 235,356 Vanda Pharmaceuticals shares in Q1 2024, an estimated $993K.
Exchange Traded Concepts first reported a position in Vanda Pharmaceuticals in Q2 2020 and held it in 10 quarters.
Exchange Traded Concepts's Vanda Pharmaceuticals position peaked at $1.01M in Q3 2023.
144 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2024.

Based on Exchange Traded Concepts's 13F filing for Q1 2024, filed 15 Apr 2024.